David Shaw’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $944K | Sell |
5,599
-83,585
| -94% | -$12.4M | ﹤0.01% | 3786 |
|
|
2026
Q1 | $11.7M | Buy |
+89,184
| New | +$11.8M | 0.01% | 1510 |
|
|
2025
Q2 | – | Sell |
-14,592
| Closed | -$1.61M | – | 4584 |
|
|
2025
Q1 | $1.61M | Sell |
14,592
-14,118
| -49% | -$1.79M | ﹤0.01% | 2762 |
|
|
2024
Q4 | $3.92M | Sell |
28,710
-140,744
| -83% | -$17.4M | ﹤0.01% | 2179 |
|
|
2024
Q3 | $19.5M | Buy |
169,454
+61,076
| +56% | +$8.37M | 0.02% | 1003 |
|
|
2024
Q2 | $14.9M | Sell |
108,378
-36,902
| -25% | -$5.06M | 0.01% | 1073 |
|
|
2024
Q1 | $20M | Buy |
145,280
+69,278
| +91% | +$9.46M | 0.02% | 923 |
|
|
2023
Q4 | $10M | Buy |
76,002
+16,940
| +29% | +$1.95M | 0.01% | 1367 |
|
|
2023
Q3 | $6.64M | Sell |
59,062
-181,422
| -75% | -$19.1M | 0.01% | 1583 |
|
|
2023
Q2 | $22.7M | Buy |
240,484
+61,378
| +34% | +$6M | 0.02% | 801 |
|
|
2023
Q1 | $18.1M | Sell |
179,106
-79,937
| -31% | -$8.32M | 0.02% | 957 |
|
|
2022
Q4 | $30.9M | Buy |
259,043
+119,781
| +86% | +$14M | 0.03% | 652 |
|
|
2022
Q3 | $14.8M | Sell |
139,262
-80,475
| -37% | -$8.17M | 0.02% | 1051 |
|
|
2022
Q2 | $21.4M | Sell |
219,737
-1,196
| -0.5% | -$110K | 0.03% | 819 |
|
|
2022
Q1 | $20.7M | Buy |
220,933
+122,957
| +125% | +$10.4M | 0.02% | 1004 |
|
|
2021
Q4 | $8.35M | Buy |
+97,976
| New | +$9.01M | 0.01% | 1839 |
|
|
2021
Q2 | – | Sell |
-8,732
| Closed | -$849K | – | 4919 |
|
|
2021
Q1 | $849K | Sell |
8,732
-1,148
| -12% | -$120K | ﹤0.01% | 3224 |
|
|
2020
Q4 | $947K | Sell |
9,880
-109,285
| -92% | -$10.6M | ﹤0.01% | 3056 |
|
|
2020
Q3 | $11.5M | Sell |
119,165
-89,040
| -43% | -$10.3M | 0.01% | 1158 |
|
|
2020
Q2 | $25.4M | Buy |
208,205
+61,371
| +42% | +$6.78M | 0.03% | 657 |
|
|
2020
Q1 | $12.7M | Buy |
146,834
+17,523
| +14% | +$1.71M | 0.02% | 867 |
|
|
2019
Q4 | $13.9M | Sell |
129,311
-75,062
| -37% | -$7.86M | 0.02% | 1009 |
|
|
2019
Q3 | $18.4M | Sell |
204,373
-113,278
| -36% | -$10.6M | 0.02% | 813 |
|
|
2019
Q2 | $26.8M | Buy |
317,651
+158,367
| +99% | +$13M | 0.03% | 611 |
|
|
2019
Q1 | $14M | Sell |
159,284
-51,239
| -24% | -$4.28M | 0.02% | 911 |
|
|
2018
Q4 | $15M | Sell |
210,523
-22,942
| -10% | -$2.2M | 0.02% | 852 |
|
|
2018
Q3 | $28.7M | Buy |
233,465
+16,462
| +8% | +$1.87M | 0.03% | 615 |
|
|
2018
Q2 | $21.3M | Buy |
217,003
+66,656
| +44% | +$5.97M | 0.03% | 692 |
|
|
2018
Q1 | $12.5M | Buy |
150,347
+44,267
| +42% | +$3.74M | 0.02% | 884 |
|
|
2017
Q4 | $8.23M | Buy |
106,080
+101,804
| +2,381% | +$6.94M | 0.01% | 1150 |
|
|
2017
Q3 | $262K | Buy |
+4,276
| New | +$226K | ﹤0.01% | 3196 |
|
|
2017
Q2 | – | Sell |
-22,114
| Closed | -$958K | – | 3486 |
|
|
2017
Q1 | $958K | Sell |
22,114
-147,281
| -87% | -$6.31M | ﹤0.01% | 2323 |
|
|
2016
Q4 | $6.55M | Sell |
169,395
-12,276
| -7% | -$556K | 0.01% | 1198 |
|
|
2016
Q3 | $9.2M | Buy |
181,671
+146,220
| +412% | +$7.28M | 0.02% | 937 |
|
|
2016
Q2 | $1.61M | Buy |
35,451
+6,541
| +23% | +$301K | ﹤0.01% | 2091 |
|
|
2016
Q1 | $1.14M | Sell |
28,910
-284,557
| -91% | -$11.3M | ﹤0.01% | 2268 |
|
|
2015
Q4 | $17.7M | Sell |
313,467
-161,085
| -34% | -$8.19M | 0.03% | 690 |
|
|
2015
Q3 | $18.9M | Buy |
474,552
+227,951
| +92% | +$11M | 0.03% | 641 |
|
|
2015
Q2 | $11.8M | Sell |
246,601
-50,691
| -17% | -$2.15M | 0.02% | 924 |
|
|
2015
Q1 | $11.8M | Sell |
297,292
-72,178
| -20% | -$2.58M | 0.02% | 871 |
|
|
2014
Q4 | $8.25M | Buy |
369,470
+73,568
| +25% | +$1.39M | 0.01% | 1231 |
|
|
2014
Q3 | $4.64M | Buy |
295,902
+172,408
| +140% | +$2.58M | 0.01% | 1622 |
|
|
2014
Q2 | $1.83M | Buy |
123,494
+75,895
| +159% | +$1.07M | ﹤0.01% | 2380 |
|
|
2014
Q1 | $766K | Buy |
47,599
+20,599
| +76% | +$352K | ﹤0.01% | 3256 |
|
|
2013
Q4 | $252K | Buy |
+27,000
| New | +$263K | ﹤0.01% | 4151 |
|
|
2013
Q3 | – | Sell |
-88,550
| Closed | -$1.19M | – | 4401 |
|
|
2013
Q2 | $1.19M | Buy |
+88,550
| New | +$1.09M | ﹤0.01% | 2571 |
|
Other funds holding NBIX
David Shaw's NBIX Position: Q2 2026 in Review
David Shaw reduced its Neurocrine Biosciences (NBIX) stake by 94% in Q2 2026, selling an estimated $12.4M and leaving 5,599 shares worth $944K. The position accounts for ﹤0.01% of the portfolio, ranked #3786.
David Shaw first reported a position in NBIX in Q2 2013 and has held it in 46 quarters since. The position peaked at $30.9M in Q4 2022. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- David Shaw held 5,599 shares of Neurocrine Biosciences worth $944K as of Q2 2026.
- David Shaw sold 83,585 Neurocrine Biosciences shares in Q2 2026, an estimated $12.4M.
- Neurocrine Biosciences made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3786 holding.
- David Shaw first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 46 quarters since.
- David Shaw's Neurocrine Biosciences position peaked at $30.9M in Q4 2022.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.